Day 1 of the Corona Remedies IPO was well received; at market close, the total subscription had reached 62%. While non-institutional investors also made modest contributions, the retail investor category demonstrated great enthusiasm by subscribing 87% of its allotted part.

As subscription days go on, the IPO is anticipated to gain momentum due to the healthcare industry’s continued resilience and investor sentiment favoring excellent pharmaceutical companies. According to analysts, investor trust is mostly fueled by the company’s robust product line and consistent financial results.

Related: Energy Startup ACS Energy Secures INR 1.1 Crore Funding Support

Retail investors were the main source of the IPO’s strong 62% overall subscription.
Breakdown thus far:

• Investors at retail: 87% signed up
• NII/HNI Category: Early interest that is moderate
• QIB Category: Anticipated to gain momentum in subsequent rounds

The subscription numbers show that mid-sized pharmaceutical companies with steady profitability and growing market reach are becoming more and more popular.

Corona Remedies has established a significant foothold in both acute and chronic therapeutic markets in India. With a wide range of products and steady financial results, the business is well-positioned for:

• Growth into further therapeutic areas
• Enhanced penetration of the domestic market
• Increased revenue growth supported by actions to strengthen the brand

Its growing margins and scalable business strategy, according to analysts, may make it a more stable long-term investment.

The GMP for the Corona Remedies IPO is estimated by early market trackers to be between ₹15 and ₹20 per share. This premium represents reasonable listing expectations in a volatile market, even though it is not very high.

As subscription demand rises in institutional categories, market experts predict that GMP may see swings. Because of the company’s solid fundamentals, experts are still bullish despite the small GMP.

A strong 87% retail booking and a 62% Day 1 subscription indicate strong demand for the Corona Remedies IPO. Analysts point to the company’s strong track record, plans for product expansion, and sectoral stability as reasons for investors to be positive despite the low grey market premium.